The paradigm of MS treatment has predominantly centred around managing immune-mediated inflammation and diminishing relapsing activity. While disease-modifying therapies continue to be important, their benefits may prove limited as patients progress into phases characterized by chronic progressive neuroaxonal injury, incomplete remyelination, and accumulated disability. This clinical limitation has caught the interest of regenerative medicine, especially in umbilical cord-derived mesenchymal stem cells (UC-MSCs). Seeking new avenues for improvement in immune modulating effects of endogenous neurorestoration, these neonatal cells are now increasingly being examined in modern day regenerative neurology to examine their potential noisome beyond innate immunomodulation; extending into dynamic influence over cellular repair and neuroprotection as well as the level of tissue recovery via refined molecular signaling.
- Mitochondrial Support and Immunometabolic Reprogramming
An exciting area of investigation in UC-MSC biology is their potential role in immunometabolism. In MS the inflammatory microenvironment is frequently dominated by activated immune populations including pro-inflammatory macrophages and pathogenic T-cell subsets, many of which depend on modified metabolic pathways that support inflammatory activity. Mesenchymal stem cells have been shown to transfer mitochondrial and other biologically relevant components with injured or dysregulated instructing cells through intercellular communication, utilizing specialized cell-interactive structures such as tunneling nanotubes (TNTs), experimentally.
This is of interest since mitochondrial support can change the functional state of immune and glial cells residing in inflamed neural tissue. Instead of sustaining a chronically deleterious inflammatory phenotype, recipient cells may adopt a more normal metabolic and immunologic signature. In this regard, UC-MSCs are being investigated as potential mediators of a microenvironmental shift from chronic neurotoxicity to a more protective and resolution-oriented state. Such alterations may also be correlated with higher levels of anti-inflammatory signals such as interleukin-10 (IL-10), to buffer the continuing tissue damage and shield vulnerable axons from further injury.
- Exosomal MicroRNA Signaling and Epigenetic Influence
The second critical component in regenerative MS research is the UC-MSC secretome with a focus on extracellular vesicles and exosomes. Given the nanoscale size of these exosomes, along with their capacity to transport proteins, lipids and regulatory nucleic acids [eg. micro RNAs (miRNAs)] while allowing distant stem cells to influence gene expression as well as guide cellular behavior. In MS, one of the main biological barriers is improper remyelination, which is sometimes ascribed to an apparent failure of oligodendrocyte progenitor cells (OPCs), which fail to properly mature and replace lost myelin.
In this context, MSC-derived exosomes are being examined for their ability to modulate the pathways governing remyelination. Experimental studies suggest that some of the miRNA correlated to MSC exosomes can modulate inhibitory molecular networks and encourage OPC differentiation (Hashimoto et al. 2016). Thus, due to this epigenetic action, UC-MSCs’ cellular therapies have gained renewed attention in promoting myelin de novo repair as a mechanism to enhance axonal conductivity and preserve the neurological function of patients with MS years after onset.
- Proteostasis, Autophagy, and Neuronal Resilience
Demyelination is not the only driver of neurodegeneration in MS. Chronic inflammation, oxidative injury, and metabolic stress may further affect proteostasis, the cellular programme that ensures protein integrity and organelle quality. When this equilibrium is upset, neurons can accumulate dysfunctional proteins and organelles (dysfunctional cellular structures), leading to endoplasmic reticulum stress and apoptosis signaling.
Umblilicle cord-derived conditioned medium (UC-MSC) mocules have shown some promise for improving neuronal stress resistance through modulation of intracellular housekeeping pathways like autophagy. They function to potentially promote the recycling and clearance of damaged cellular material through the release of trophic and regulatory factors which, in turn, stabilize neurons in chronically inflamed settings. This approach to investigation is significant because it indicates UC-MSCs may be responsible for maintaining not only immune control, but also neural structure and function. In the wider clinical context, this may be important for blunting the progression from relapsing disease patterns and increasing neurodegenerative progression.
- Blood–Brain Barrier Repair and Targeted Homing Mechanisms
Blood–brain barrier (BBB) dysfunction allowing the entry of autoreactive immune cells to the CNS is a key feature characterizing MS pathophysiology. In this vicinity, UC-MSCs are guided toward the injured organ by chemotactic signals released from damaged tissues (including CXCR4/SDF-1 axis), therefore having become a focus of interest. This homing behavior is believed to assist cells in navigating between sites of inflammation and neural damage.
Inside or near the tissue environments with injury, UC-MSCs could exert protective effects in the neurovascular interface mediated via paracrine factors associated to endothelial stabilization and barrier support. This theoretically could decrease ongoing immune infiltration as well as strengthen integrity of the structural stability of the BBB. This dual function—the migratory response toward injury together with supportive roles during vascular repair—has rendered UC-MSCs especially attractive in regenerative MS studies, as both immune infiltration and tissue damage are key drivers of disease progression.
- Clinical Translation of Regenerative Medicine in Thailand
The application of UC-MSCs in MS represents a more specific and detailed application for their use, mirroring the broader development of Thailand’s regenerative medicine infrastructure. In the context of advanced clinical programs, significant efforts are invested to maximize cell quality through optimized culture conditions, viability thresholds, and procedural uniformity prior to administration. Other centres also focus on culture conditions adapted to preserve UC-MSC biological activity and “stemness” in the process of expansion.
From a translational perspective, treatment strategies could be mediated through diverse routes of delivery based on clinical goals. While intravenous administration is popularly addressed under the systemic immunomodulation, intrathecal delivery have been investigated as a means of proximity approach of biologically active cells or signaling factors to the central nervous system setting. In certain programs, these cellular approaches are combined with systematic neuro-rehabilitation, on the presumption that biological support paired with functional training may be best to use in combination.
Thailand’s role in this regard is not just related to availability of treatment, but also with the development of multidisciplinary programmes integrating cell processing, neurologic assessment, rehabilitation planning and continuous monitoring. This has led to increasing interest in the country as a location for patients with complex neurological conditions requiring advanced supportive care.
- Concluding Perspective
The therapeutic paradigm in Multiple Sclerosis is slowly shifting, from an anti-inflammatory model to one that embraces repair, resilience and neuroprotection as well. This new paradigm of immediate brain response to injury is leading to a close investigation of UC-MSCs given their wide range of biological activity including potentially mitochondrial support, exosomal regulation, BBB stabilization, immunomodulation and neuroprotection at the tissue level.
Interpretation, however, still needs to be carefully considered. Cortex-based therapy should be understood not as a definitive cure for MS, but rather one of an array of supportive regenerative strategies undergoing continual scientific and clinical evolution; crucially, all relevant targeting mechanisms currently inaccessible to standard therapies, most notably remyelination failure and chronic neurodegeneration.
The crosstalk between UC-MSCs and the inflamed CNS may provide a significant avenue for MS therapy in this context as regenerative neurology progresses. In Thailand, this field is evolving as part of a systematic approach involving well-organized clinical contexts in the broader context that supports long-term neurological stability, function, and recovery of individuals living with Multiple Sclerosis.